Profusa, Inc.

Profusa, Inc. (ticker: PFSA) filed an 8-K with the Securities and Exchange Commission on November 10, 2022, reporting a material corporate event tied to its SPAC-related transaction. Profusa is a medical technology company focused on developing injectable continuous biosensors that monitor biochemical markers in the body in real time, positioning it within the digital health and medical devices sector. The company pursued a de-SPAC path to the public markets, consistent with the broader wave of healthcare-adjacent SPAC transactions that characterized the early 2020s. The November 2022 filing reflects ongoing post-combination disclosure obligations common to companies that completed blank-check mergers during that period. Sign up at SpacDesk for the full transaction timeline, sponsor details, and filing history on PFSA.